To appraise the clinical and cost effectiveness of liposomal cytarabine and daunorubicin within its marketing authorisation for untreated, high risk, acute myeloid leukaemia.
Status In progress
Process STA
ID number 1225

Provisional Schedule

Expected publication 09 January 2019

Project Team

Project lead Stephanie Callaghan

Email enquiries


Key events during the development of the guidance:

Date Update
21 February 2018 Invitation to participate
18 August 2017 - 18 September 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
18 August 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance